Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 5/20 | 0.44 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.42 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | THPO | P40225 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.38 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
| ▸ | GNPAT | O15228 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL215383 | 1.00 | FOLH1 (0.44) | FOLH1RIMKLANAALAD2KDM4EMAPT | |
| SCHEMBL1289325 | 0.82 | KDM4E (0.61) | FOLH1RIMKLANAALAD2KDM4EMAPT | |
| SCHEMBL12461743 | 0.82 | GNPAT (0.52) | FOLH1RIMKLANAALAD2TGFBR1GNPAT | |
| SCHEMBL478268 | 0.82 | KDM4E (0.61) | FOLH1RIMKLANAALAD2KDM4EMAPT | |
| SCHEMBL478269 | 0.82 | KDM4E (0.61) | FOLH1RIMKLANAALAD2KDM4EMAPT | |
| SCHEMBL1147075 | 0.80 | TGFBR1 (0.47) | FOLH1RIMKLANAALAD2KDM4EMAPT | |
| SCHEMBL1147073 | 0.80 | TGFBR1 (0.47) | FOLH1RIMKLANAALAD2KDM4EMAPT | |
| Hydrazine SCHEMBL9545541 | 0.79 | SMN1; SMN2 (0.64) | FOLH1RIMKLANAALAD2KDM4EMAPT | |
| SCHEMBL4649931 | 0.79 | GNPAT (0.42) | FOLH1RIMKLANAALAD2KDM4EMAPT | |
| SCHEMBL4649933 | 0.79 | GNPAT (0.42) | FOLH1RIMKLANAALAD2KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160338959-A1 | DRUG LOADED POLYMERIC NANOPARTICLES AND METHODS OF MAKING AND USING SAME | PFIZER INC. | 2016-11-24 | — | — | US | disclosed |
| US-9375481-B2 | Drug loaded polymeric nanoparticles and methods of making and using same | BIND THERAPEUTICS, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20140356444-A1 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same | BIND THERAPEUTICS, INC. (US) | 2014-12-04 | — | — | US | disclosed |
| US-20130302432-A1 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same | PFIZER INC. | 2013-11-14 | — | — | US | disclosed |
| US-20130280339-A1 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same | PFIZER INC. | 2013-10-24 | — | — | US | disclosed |
| US-20130251757-A1 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same | PFIZER INC. | 2013-09-26 | — | — | US | disclosed |
| US-8420123-B2 | Drug loaded polymeric nanoparticles and methods of making and using same | BIND BIOSCIENCES, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-8246968-B2 | Cancer cell targeting using nanoparticles | BIND BIOSCIENCES, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8206747-B2 | Drug loaded polymeric nanoparticles and methods of making and using same | BIND BIOSCIENCES, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-8088768-B2 | Protein kinase and phosphatase inhibitors | THE RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK (US) | 2012-01-03 | — | — | US | disclosed |
| US-20080004241-A1 | 2-carboxamide substituted indoles; osteoporosis, hepatitis B, ophthalmic disease, diabetes, atherosclerosis, obesity, chronic neuropathic pain, stroke; protein tyrosine kinase (PTK) inhibitors; 5-fluoro-3-phenylindole-2-carboxamides | OAKTREE FUND ADMINISTRATION, LLC | 2008-01-03 | — | — | US | disclosed |
| US-7070936-B1 | Method for designing protein kinase inhibitors | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2006-07-04 | — | — | US | disclosed |
| US-20060089401-A1 | Kinase inhibitors | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2006-04-27 | — | — | US | disclosed |
| US-7005445-B2 | Protein kinase and phosphatase inhibitors and methods for designing them | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2006-02-28 | — | — | US | disclosed |
| US-20060030544-A1 | Protein kinase and phosphatase inhibitors and methods for designing them | RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, THE | 2006-02-09 | — | — | US | disclosed |
| EP-1444204-A1 | PROTEIN KINASE AND PHOSPHATASE INHIBITORS, METHODS FOR DESIGNING THEM, AND METHODS OF USING THEM | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20030166615-A1 | Protein kinase and phosphatase inhibitors and methods for designing them | RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, THE | 2003-09-04 | — | — | US | disclosed |
| WO-2003035621-A1 | PROTEIN KINASE AND PHOSPHATASE INHIBITORS, METHODS FOR DESIGNING THEM, AND METHODS OF USING THEM | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2003-05-01 | — | — | WO | disclosed |
| EP-1147214-A1 | A NOVEL METHOD FOR DESIGNING PROTEIN KINASE INHIBITORS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000042213-A1 | A NOVEL METHOD FOR DESIGNING PROTEIN KINASE INHIBITORS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130302432-A1 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same | CD47, LPXN, CD44 | FOLH1 173/4885RIMKLA 1707/4885NAALAD2 2614/4885 |
| US-20160338959-A1 | DRUG LOADED POLYMERIC NANOPARTICLES AND METHODS OF MAKING AND USING SAME | LDHA, LDHB, LPXN | FOLH1 177/4885RIMKLA 1489/4885NAALAD2 2442/4885 |
| US-20060030544-A1 | Protein kinase and phosphatase inhibitors and methods for designing them | PTPN5, PTPN2, PTPN6 | FOLH1 1287/4885RIMKLA 3221/4885NAALAD2 1317/4885 |
| US-20130280339-A1 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same | CD47, LPXN, CD44 | FOLH1 173/4885RIMKLA 1707/4885NAALAD2 2614/4885 |
| US-20140356444-A1 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same | LDHA, LDHB, LPXN | FOLH1 177/4885RIMKLA 1489/4885NAALAD2 2442/4885 |
| US-20130251757-A1 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same | LDHA, LDHB, LPXN | FOLH1 177/4885RIMKLA 1489/4885NAALAD2 2442/4885 |
| US-20060089401-A1 | Kinase inhibitors | MAP3K5, MAP3K20, MAP4K5 | FOLH1 1160/4885RIMKLA 2663/4885NAALAD2 1134/4885 |
| US-20080004241-A1 | 2-carboxamide substituted indoles; osteoporosis, hepatitis B, ophthalmic disease, diabetes, atherosclerosis, obesity, chronic neuropathic pain, stroke; protein tyrosine kinase (PTK) inhibitors; 5-fluoro-3-phenylindole-2-carboxamides | PTK2B, GRK2, FRK | FOLH1 4100/4885RIMKLA 2976/4885NAALAD2 2430/4885 |
| US-20030166615-A1 | Protein kinase and phosphatase inhibitors and methods for designing them | PTPN5, PTPN2, PTPN6 | FOLH1 1287/4885RIMKLA 3221/4885NAALAD2 1317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.